Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Bulk Drug Intermediates >  Retigabine Dihydrochloride

Retigabine Dihydrochloride

Basic information Safety Supplier Related

Retigabine Dihydrochloride Basic information

Product Name:
Retigabine Dihydrochloride
Synonyms:
  • D 20443
  • Ethyl [2-amino-4-[[(4-fluorophenyl)methyl]amino]phenyl]carbamate Dihydrochloride
  • N-(2-Amino-4-(4-fluorobenzylamino)phenyl)carbamic Acid Ethyl Ester Dihydrochloride
  • Retigabine Dihydrochloride
  • Retigabine HCl
  • D 20443 dihydrochloride
  • Retigabine 2HCL
  • D20443 dihydrochloride
CAS:
150812-13-8
MF:
C16H20Cl2FN3O2
MW:
376.2
EINECS:
2017-001-1
Product Categories:
  • API
  • Chemical Amines
  • Amines
  • Aromatics
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
Mol File:
150812-13-8.mol
More
Less

Retigabine Dihydrochloride Chemical Properties

Melting point:
168-170°C
storage temp. 
Hygroscopic, -20°C Freezer, Under Inert Atmosphere
solubility 
≥18.8 mg/mL in DMSO; ≥52.4 mg/mL in H2O with gentle warming; ≥8.71 mg/mL in EtOH with gentle warming and ultrasonic
form 
solid
Stability:
Hygroscopic
More
Less

Retigabine Dihydrochloride Usage And Synthesis

Chemical Properties

Off-White Powder

Drug interactions

 A clinical interaction study showed that there was no pharmacokinetic interaction between phenobarbitone and retigabine in healthy subjects. Thus, no dosage adjustment is likely to be necessary when phenobarbitone and retigabine are coadministered to patients 

Uses

A new experimental anticonvulsant drug. Anxiolytic.
Retigabine Dihydrochloride (0.1 ~ 10 μM) induced a potassium current and hyperpolarized CHO-KCNQ2/Q3 cells but not in wild-type cells. In the 6-Hz psychomotor seizure model, Retigabine Dihydrochloride dose-dependently blocked seizures induced by either 32 or 44 mA current stimulation.

Biological Activity

Retigabine is a first-in-class k+ channel (kcnq) opener. kcnq channels are reported to be expressed predominantly in neurons and are critical determinants of cellular excitability, as shown by the occurrence of human genetic mutations in kcnq channels which underlie inheritable disorders including the syndrome of benign familial neonatal convulsions.

in vitro

retigabine was found to combine a novel mode of actions, which were namely potassium channel opening (kcnq2, kcnq3 as well as kcnq4 channels). retigabine also showed activities with some potentiation of gamma amino butyric acid (gaba)-evoked currents at its higher concentrations [1].

in vivo

animal models of epileptic seizures showed that retigabine treatment was effective at an oral dose as low as 0.01 mg/kg. studies performed in mice also indicated that combining retigabine with another anticonvulsant agent leads to an additive effect [1].

References

[1] ferron gm,patat a,parks v,rolan p,troy sm. lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. br j clin pharmacol.2003 jul;56(1):39-45.

Retigabine DihydrochlorideSupplier

Shanghai Huici Pharmaceutical Technology Co., LTD Gold
Tel
19372841038 19372841038
Email
lixing@pharmahuici.com
Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Chembest Research Laboratories Limited
Tel
021-20908456
Email
sales@BioChemBest.com
Wuhu Huaren Science and Technology Co., Ltd.
Tel
0553-0553-5842013-801 18155347026
Email
sale@huarensh.com